INM — Mentari Therapeutics Share News
0.000.00%
Last trade - 00:00U.S. STOCKS ON THE MOVE-OFS Credit, Nike, Elevance Health
U.S. STOCKS ON THE MOVE-CytoSorbents, Tapestry, Wayfair
U.S. STOCKS ON THE MOVE-Mogu, Energy firms, Kroger
InMed Pharmaceuticals surges, catches retail investor attention
U.S. STOCKS ON THE MOVE-Ecoark, Akero, Apple
U.S. STOCKS ON THE MOVE-Annovis Bio, Helbiz, SuperCom
U.S. STOCKS ON THE MOVE-Centennial, La-Z-Boy, SciSparc
InMed Pharmaceuticals down after share consolidation plan
Brief: Inmed Announces Share Consolidation To Meet Nasdaq Listing Criteria
Brief: InMed Announces Changes To Its Board Of Directors
Brief: InMed Pharmaceuticals Announces Update On Phase 2 Clinical Trial Investigating Inm-755 Cannabinol Cream For Epidermolysis Bullosa
Brief: Inmed Announces Appointment Of Chief Operating Officer
Brief: InMed Pharmaceuticals Says Receives Nasdaq Notification Regarding Minimum Bid Price Compliance
Brief: InMed Pharma Was Notified That Average Closing Bid Price Of Its Common Shares Was Below Minimum Requirement For Continued Listing On Nasdaq
InMed Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: InMed Pharmaceuticals Reports Q3 Net Loss Per Share Of $0.25
InMed Pharmaceuticals Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: InMed To Supply Rare Cannabinoids To Radicle Science’S “Radicle Energy Study”
Brief: InMed Advances Collaboration Agreement with Leading Cannabinoid Research Expert